TOP NEWS!!!!!!!!!! 24/7

By -
NEWS

Comments

Post a Comment

Word verification with comments to show us your human and not auto spam junk.

Popular posts from this blog

Myasthenia Gravis vs. Lambert Eaton Syndrome ?

By -
Image
Question: What is the difference between Myasthenia Gravis and Lambert-Eaton syndrome? How do doctors differentiate between the two in diagnosis? Is the treatment similar? Answer: Myasthenia gravis causes muscle weakness that patients usually appreciate becoming significantly worse with activity. Double vision, swallowing and speaking abnormalities, and difficulty walking and using the arms are common symptoms. Lambert-Eaton may produce similar symptoms, but double vision is less common. Muscle aches are more common and patients often have dry mouth. Patients may also have impotence, constipation, impaired sweating, and blurred vision. Myasthenia gravis is caused by antibodies against acetylcholine receptor and compromise the muscle side of the nerve-muscle communication point. Lambert-Eaton syndrome appears to be caused most often by antibodies to calcium channels of the nerve. Lambert-Eaton is often triggered by the development of a lung cancer. An EMG test can differentiate ...
Read more

The Shuman Law Firm Investigates Catalyst Pharmaceutical Partners, Inc.

By -
The Shuman Law Firm Investigates Catalyst Pharmaceutical Partners, Inc. BOULDER, Colo., May 15, 2014 (BUSINESS WIRE) --  The Shuman Law Firm  announces that it is investigating potential claims against certain officers and directors of Catalyst Pharmaceutical Partners, Inc. (“Catalyst” or the “Company”) (Nasdaq:  CPRX  ). Catalyst is as a Florida-based development-stage specialty pharmaceutical company. Catalyst’s major product is Firdapse which is used to treat Lambert-Eaton Myasthenic Syndrome (“LEMS”). The Firm’s investigation relates to allegations raised in a class action lawsuit against the Company relating to its disclosures regarding Firdapse and LEMS. The class action complaint alleges that the Company’s senior officers and/or directors mislead investors by (i) concealing that a competitor has been providing patients for free with a drug that is nearly biologically equivalent to the drug for which Catalyst seeks  Food and Drug Administration  ...
Read more